| Authors: |
Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jegede OA; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Grilley-Olson JE; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Lauring JD; Johns Hopkins School of Medicine, Baltimore, MD., Mitchell EP; Thomas Jefferson University, Philadelphia, PA., Zwiebel JA; National Cancer Institute, Bethesda, MD., Gray RJ; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; National Cancer Institute, Bethesda, MD., Rubinstein LV; National Cancer Institute, Bethesda, MD., Patton D; National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope Comprehensive Cancer Center, Duarte, CA., Kono SA; Colorado Permanente Medical Group, Lone Tree, CO., Ford JM; Stanford University, Stanford, CA., Garcia AA; Louisiana State University Health Science Center, New Orleans, LA., Sui XD; Providence Regional Cancer System, Lacey, WA., Siegel RD; Bon Secours St Francis Hospital, Greenville, SC., Slomovitz BM; University of Miami, Miami, FL., Conley BA; National Cancer Institute, Bethesda, MD., Arteaga CL; University of Texas Southwestern Medical Center, Dallas, TX., Harris LN; National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital, Boston, MA. |
